Does the media prefer FBIO or SABS?

In the previous week, SAB Biotherapeutics had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 4 mentions for SAB Biotherapeutics and 2 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 1.26 beat SAB Biotherapeutics' score of 0.47 indicating that Fortress Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SAB Biotherapeutics 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is CDXS or FBIO more profitable?

Fortress Biotech has a net margin of 193.12% compared to Codexis' net margin of -40.97%. Fortress Biotech's return on equity of 109.66% beat Codexis' return on equity. Company Net Margins Return on Equity Return on Assets Codexis -40.97% -68.09% -23.72% Fortress Biotech 193.12% 109.66% 45.56%

Does the media refer more to CDXS or FBIO?

In the previous week, Codexis and Codexis both had 2 articles in the media. Fortress Biotech's average media sentiment score of 1.26 beat Codexis' score of 0.94 indicating that Fortress Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Codexis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortress Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is FBIO or AGEN more profitable?

Fortress Biotech has a net margin of 193.12% compared to Agenus' net margin of 50.49%. Fortress Biotech's return on equity of 109.66% beat Agenus' return on equity. Company Net Margins Return on Equity Return on Assets Fortress Biotech 193.12% 109.66% 45.56% Agenus 50.49% -31.66% 42.71%

Does the media prefer FBIO or AGEN?

In the previous week, Fortress Biotech and Fortress Biotech both had 2 articles in the media. Fortress Biotech's average media sentiment score of 1.26 beat Agenus' score of 1.26 indicating that Fortress Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fortress Biotech 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Agenus 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate FBIO or DOMH?

Fortress Biotech presently has a consensus price target of $17.00, indicating a potential upside of 551.34%. Given Fortress Biotech's stronger consensus rating and higher possible upside, equities analysts clearly believe Fortress Biotech is more favorable than Dominari. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Fortress Biotech 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Dominari 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is FBIO or DOMH more profitable?

Fortress Biotech has a net margin of 193.12% compared to Dominari's net margin of -31.37%. Fortress Biotech's return on equity of 109.66% beat Dominari's return on equity. Company Net Margins Return on Equity Return on Assets Fortress Biotech 193.12% 109.66% 45.56% Dominari -31.37% -206.20% -155.26%

Fortress Biotech (FBIO) Competitors

$2.61 -0.04 (-1.51%)

Closing price 06/3/2026 04:00 PM Eastern

Extended Trading

$2.60 -0.01 (-0.57%)

As of 06/3/2026 06:55 PM Eastern

Compare

FBIO vs. SABS, CDXS, AGEN, SGMO, and DOMH

Should you buy Fortress Biotech stock or one of its competitors? MarketBeat compares Fortress Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fortress Biotech include SAB Biotherapeutics (SABS), Codexis (CDXS), Agenus (AGEN), Sangamo Therapeutics (SGMO), and Dominari (DOMH). These companies are all part of the "biotechnology" industry.

How does Fortress Biotech compare to SAB Biotherapeutics?

Fortress Biotech (NASDAQ:FBIO) and SAB Biotherapeutics (NASDAQ:SABS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their analyst recommendations, profitability, valuation, institutional ownership, earnings, media sentiment, risk and dividends.

Fortress Biotech currently has a consensus price target of $17.00, suggesting a potential upside of 551.34%. SAB Biotherapeutics has a consensus price target of $11.00, suggesting a potential upside of 227.38%. Given Fortress Biotech's higher possible upside, research analysts clearly believe Fortress Biotech is more favorable than SAB Biotherapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
SAB Biotherapeutics	1 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.80

SAB Biotherapeutics has lower revenue, but higher earnings than Fortress Biotech. SAB Biotherapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.37	$6.82M	$3.17	0.82
SAB Biotherapeutics	$1.32M	194.63	$13.27M	-$2.11	N/A

96.5% of Fortress Biotech shares are owned by institutional investors. Comparatively, 7.8% of SAB Biotherapeutics shares are owned by institutional investors. 28.5% of Fortress Biotech shares are owned by insiders. Comparatively, 25.1% of SAB Biotherapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Fortress Biotech has a net margin of 193.12% compared to SAB Biotherapeutics' net margin of 0.00%. Fortress Biotech's return on equity of 109.66% beat SAB Biotherapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	193.12%	109.66%	45.56%
SAB Biotherapeutics	N/A	-0.29%	-0.25%

Fortress Biotech has a beta of 1.22, indicating that its share price is 22% more volatile than the broader market. Comparatively, SAB Biotherapeutics has a beta of 0.54, indicating that its share price is 46% less volatile than the broader market.

In the previous week, SAB Biotherapeutics had 2 more articles in the media than Fortress Biotech. MarketBeat recorded 4 mentions for SAB Biotherapeutics and 2 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 1.26 beat SAB Biotherapeutics' score of 0.47 indicating that Fortress Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
SAB Biotherapeutics	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Fortress Biotech beats SAB Biotherapeutics on 11 of the 17 factors compared between the two stocks.

How does Fortress Biotech compare to Codexis?

Codexis (NASDAQ:CDXS) and Fortress Biotech (NASDAQ:FBIO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

78.5% of Codexis shares are held by institutional investors. Comparatively, 96.5% of Fortress Biotech shares are held by institutional investors. 3.5% of Codexis shares are held by insiders. Comparatively, 28.5% of Fortress Biotech shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Codexis has a beta of 2.48, suggesting that its stock price is 148% more volatile than the broader market. Comparatively, Fortress Biotech has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market.

Fortress Biotech has a net margin of 193.12% compared to Codexis' net margin of -40.97%. Fortress Biotech's return on equity of 109.66% beat Codexis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Codexis	-40.97%	-68.09%	-23.72%
Fortress Biotech	193.12%	109.66%	45.56%

Fortress Biotech has lower revenue, but higher earnings than Codexis. Codexis is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Codexis	$70.39M	3.51	-$43.97M	-$0.37	N/A
Fortress Biotech	$63.26M	1.37	$6.82M	$3.17	0.82

In the previous week, Codexis and Codexis both had 2 articles in the media. Fortress Biotech's average media sentiment score of 1.26 beat Codexis' score of 0.94 indicating that Fortress Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Codexis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortress Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Codexis currently has a consensus target price of $5.00, suggesting a potential upside of 83.82%. Fortress Biotech has a consensus target price of $17.00, suggesting a potential upside of 551.34%. Given Fortress Biotech's stronger consensus rating and higher possible upside, analysts plainly believe Fortress Biotech is more favorable than Codexis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Codexis	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Fortress Biotech beats Codexis on 12 of the 15 factors compared between the two stocks.

How does Fortress Biotech compare to Agenus?

Fortress Biotech (NASDAQ:FBIO) and Agenus (NASDAQ:AGEN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability.

Fortress Biotech presently has a consensus price target of $17.00, indicating a potential upside of 551.34%. Agenus has a consensus price target of $23.00, indicating a potential upside of 614.29%. Given Agenus' higher probable upside, analysts clearly believe Agenus is more favorable than Fortress Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Agenus	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Fortress Biotech and Fortress Biotech both had 2 articles in the media. Fortress Biotech's average media sentiment score of 1.26 beat Agenus' score of 1.26 indicating that Fortress Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fortress Biotech	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Agenus	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 61.5% of Agenus shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by insiders. Comparatively, 5.5% of Agenus shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Fortress Biotech has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, Agenus has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market.

Fortress Biotech has a net margin of 193.12% compared to Agenus' net margin of 50.49%. Fortress Biotech's return on equity of 109.66% beat Agenus' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	193.12%	109.66%	45.56%
Agenus	50.49%	-31.66%	42.71%

Fortress Biotech has higher earnings, but lower revenue than Agenus. Fortress Biotech is trading at a lower price-to-earnings ratio than Agenus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.37	$6.82M	$3.17	0.82
Agenus	$114.20M	1.17	$120K	$1.59	2.03

Summary

Fortress Biotech beats Agenus on 11 of the 15 factors compared between the two stocks.

How does Fortress Biotech compare to Sangamo Therapeutics?

Fortress Biotech (NASDAQ:FBIO) and Sangamo Therapeutics (NASDAQ:SGMO) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, risk, analyst recommendations, media sentiment, profitability, valuation and dividends.

Fortress Biotech currently has a consensus target price of $17.00, indicating a potential upside of 551.34%. Sangamo Therapeutics has a consensus target price of $5.50, indicating a potential upside of 2,443.94%. Given Sangamo Therapeutics' higher probable upside, analysts plainly believe Sangamo Therapeutics is more favorable than Fortress Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Sangamo Therapeutics	2 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.75

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 56.9% of Sangamo Therapeutics shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by insiders. Comparatively, 4.1% of Sangamo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Fortress Biotech has higher revenue and earnings than Sangamo Therapeutics. Sangamo Therapeutics is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.37	$6.82M	$3.17	0.82
Sangamo Therapeutics	$39.55M	2.26	-$122.93M	-$0.38	N/A

Fortress Biotech has a net margin of 193.12% compared to Sangamo Therapeutics' net margin of -310.81%. Fortress Biotech's return on equity of 109.66% beat Sangamo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	193.12%	109.66%	45.56%
Sangamo Therapeutics	-310.81%	-2,662.06%	-132.12%

In the previous week, Sangamo Therapeutics had 4 more articles in the media than Fortress Biotech. MarketBeat recorded 6 mentions for Sangamo Therapeutics and 2 mentions for Fortress Biotech. Fortress Biotech's average media sentiment score of 1.26 beat Sangamo Therapeutics' score of 0.14 indicating that Fortress Biotech is being referred to more favorably in the media.

Company	Overall Sentiment
Fortress Biotech	Positive
Sangamo Therapeutics	Neutral

Fortress Biotech has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market. Comparatively, Sangamo Therapeutics has a beta of 1.04, suggesting that its share price is 4% more volatile than the broader market.

Summary

Fortress Biotech beats Sangamo Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Fortress Biotech compare to Dominari?

Fortress Biotech (NASDAQ:FBIO) and Dominari (NASDAQ:DOMH) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, media sentiment, analyst recommendations, dividends and profitability.

Fortress Biotech has higher earnings, but lower revenue than Dominari. Dominari is trading at a lower price-to-earnings ratio than Fortress Biotech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fortress Biotech	$63.26M	1.37	$6.82M	$3.17	0.82
Dominari	$123.10M	0.60	-$22.43M	-$4.03	N/A

Fortress Biotech has a net margin of 193.12% compared to Dominari's net margin of -31.37%. Fortress Biotech's return on equity of 109.66% beat Dominari's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fortress Biotech	193.12%	109.66%	45.56%
Dominari	-31.37%	-206.20%	-155.26%

In the previous week, Fortress Biotech had 1 more articles in the media than Dominari. MarketBeat recorded 2 mentions for Fortress Biotech and 1 mentions for Dominari. Dominari's average media sentiment score of 1.47 beat Fortress Biotech's score of 1.26 indicating that Dominari is being referred to more favorably in the news media.

Company	Overall Sentiment
Fortress Biotech	Positive
Dominari	Positive

Fortress Biotech presently has a consensus price target of $17.00, indicating a potential upside of 551.34%. Given Fortress Biotech's stronger consensus rating and higher possible upside, equities analysts clearly believe Fortress Biotech is more favorable than Dominari.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fortress Biotech	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Dominari	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Fortress Biotech has a beta of 1.22, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Dominari has a beta of 0.8, suggesting that its stock price is 20% less volatile than the broader market.

96.5% of Fortress Biotech shares are held by institutional investors. Comparatively, 42.5% of Dominari shares are held by institutional investors. 28.5% of Fortress Biotech shares are held by company insiders. Comparatively, 55.3% of Dominari shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Fortress Biotech beats Dominari on 13 of the 16 factors compared between the two stocks.

Get Fortress Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FBIO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

FBIO vs. The Competition

Export

Metric	Fortress Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$88.03M	$3.24B	$6.47B	$12.54B
Dividend Yield	N/A	2.38%	2.69%	5.22%
P/E Ratio	0.82	17.78	22.17	24.18
Price / Sales	1.37	315.63	520.79	112.26
Price / Cash	N/A	111.64	41.34	57.13
Price / Book	1.31	6.63	9.84	6.72
Net Income	$6.82M	$24.20M	$3.57B	$337.19M
7 Day Performance	-7.12%	-4.39%	-2.46%	-0.74%
1 Month Performance	N/A	N/A	N/A	-1.69%
1 Year Performance	41.08%	45.50%	26.49%	33.10%

Fortress Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
FBIO Fortress Biotech	3.8958 of 5 stars	$2.61 -1.5%	$17.00 +551.3%	+41.8%	$88.03M	$63.26M	0.82	170	Positive News
SABS SAB Biotherapeutics	3.6465 of 5 stars	$3.44 -4.4%	$11.00 +219.8%	+80.6%	$275.27M	$1.32M	N/A	140	Gap Up
CDXS Codexis	3.2861 of 5 stars	$2.67 -3.6%	$5.00 +87.3%	+16.2%	$251.78M	$70.39M	N/A	250
AGEN Agenus	2.3308 of 5 stars	$3.48 -0.6%	$14.50 +316.7%	-35.6%	$145.75M	$114.20M	2.19	440	Positive News
SGMO Sangamo Therapeutics	2.5262 of 5 stars	$0.21 -2.9%	$5.50 +2,502.9%	-56.8%	$90.19M	$39.55M	N/A	480	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:FBIO) was last updated on 6/4/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fortress Biotech (FBIO) Competitors

FBIO vs. SABS, CDXS, AGEN, SGMO, and DOMH

How does Fortress Biotech compare to SAB Biotherapeutics?

Summary

How does Fortress Biotech compare to Codexis?

Summary

How does Fortress Biotech compare to Agenus?

Summary

How does Fortress Biotech compare to Sangamo Therapeutics?

Summary

How does Fortress Biotech compare to Dominari?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO vs. The Competition

Fortress Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fortress Biotech (FBIO) Competitors

FBIO vs. SABS, CDXS, AGEN, SGMO, and DOMH

How does Fortress Biotech compare to SAB Biotherapeutics?

Do analysts rate FBIO or SABS?

Which has stronger earnings and valuation, FBIO or SABS?

Do insiders & institutionals hold more shares of FBIO or SABS?

Is FBIO or SABS more profitable?

Which has more volatility and risk, FBIO or SABS?

Does the media prefer FBIO or SABS?

Summary

How does Fortress Biotech compare to Codexis?

Do insiders and institutionals hold more shares of CDXS or FBIO?

Which has more volatility & risk, CDXS or FBIO?

Is CDXS or FBIO more profitable?

Which has preferable earnings and valuation, CDXS or FBIO?

Does the media refer more to CDXS or FBIO?

Do analysts recommend CDXS or FBIO?

Summary

How does Fortress Biotech compare to Agenus?

Do analysts prefer FBIO or AGEN?

Does the media prefer FBIO or AGEN?

Do insiders & institutionals believe in FBIO or AGEN?

Which has more volatility & risk, FBIO or AGEN?

Is FBIO or AGEN more profitable?

Which has higher earnings & valuation, FBIO or AGEN?

Summary

How does Fortress Biotech compare to Sangamo Therapeutics?

Do analysts rate FBIO or SGMO?

Do insiders and institutionals have more ownership in FBIO or SGMO?

Which has preferable valuation & earnings, FBIO or SGMO?

Is FBIO or SGMO more profitable?

Does the media prefer FBIO or SGMO?

Which has more risk and volatility, FBIO or SGMO?

Summary

How does Fortress Biotech compare to Dominari?

Which has stronger valuation and earnings, FBIO or DOMH?

Is FBIO or DOMH more profitable?

Does the media favor FBIO or DOMH?

Do analysts rate FBIO or DOMH?

Which has more volatility and risk, FBIO or DOMH?

Do institutionals & insiders have more ownership in FBIO or DOMH?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

FBIO vs. The Competition

Fortress Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools